Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2019 Oct 26;179(2):337–347. doi: 10.1007/s10549-019-05473-9

Figure 1. Selection of molecular correlate candidate drugs.

Figure 1.

Twenty-three TNBC cell lines were treated with a panel of drugs yielding EC50 curves. The EC50s were used to derive DSS3 values. The IQR and Median DSS3 was plotted. Compounds with an IQR above 15 or median above 20 were prioritized, resulting in 12 drugs prioritized as molecular correlate targets. Correlations with molecular profiling yielded 6 sets of candidate molecular correlates (red).